

CLAIMS

CLAIM 1

6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-1-((3-methyl-1,2,4-thiadiazol-5-yl)methyl)-1H-imidazo[4,5-b]pyridine, or a salt, hydrate or solvate thereof.

CLAIM 2

1-((5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)methyl)-6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-1H-imidazo[4,5-b]pyridine, or a salt, hydrate or solvate thereof.

CLAIM 3

1-((5-(1,1-difluoroethyl)-1,3,4-oxadiazol-2-yl)methyl)-6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-1H-imidazo[4,5-b]pyridine, or a salt, hydrate or solvate thereof.

CLAIM 4

1-((5-((1R)-1-fluoroethyl)-1,3,4-oxadiazol-2-yl)methyl)-6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-1H-imidazo[4,5-b]pyridine, or a salt, hydrate or solvate thereof.

CLAIM 5

A medicament comprising the compound or salt, hydrate or solvate thereof according to any one of claims 1 to 4.

CLAIM 6

The medicament according to claim 5, which is a CLK inhibitor.

CLAIM 7

The medicament according to claim 5, which is a prophylactic or therapeutic agent for cancer.

CLAIM 8

The compound or salt, hydrate or solvate thereof according to any one of claims 1 to 4 for use in inhibiting CLK in a mammal, wherein an effective amount of the compound or a salt, hydrate or solvate thereof is to be administered to the mammal.

CLAIM 9

The compound or salt, hydrate or solvate thereof according to any one of claims 1 to 4 for use in the prevention or treatment of cancer.

5

CLAIM 10

Use of the compound or salt, hydrate or solvate thereof according to any one of claims 1 to 4 in the manufacture of a medicament for the prophylaxis or treatment of cancer.

CLAIM 11

10 The compound or salt, hydrate or solvate thereof according to any one of claims 1 to 4 for use in medicine.